Literature DB >> 34415189

Sphingosine-1-phosphate interactions in the spleen and heart reflect extent of cardiac repair in mice and failing human hearts.

SiddabasaveGowda B Gowda1, Divyavani Gowda1, Vasundhara Kain2, Hitoshi Chiba3, Shu-Ping Hui1, Charles E Chalfant4,5, Vibhu Parcha6, Pankaj Arora6, Ganesh V Halade2.   

Abstract

Sphingosine-1-phosphate (S1P) is a bioactive mediator in inflammation. Dysregulated S1P is demonstrated as a cause of heart failure (HF). However, the time-dependent and integrative role of S1P interaction with receptors in HF is unclear after myocardial infarction (MI). In this study, the sphingolipid mediators were quantified in ischemic human hearts. We also measured the time kinetics of these mediators post-MI in murine spleen and heart as an integrative approach to understand the interaction of S1P and respective S1P receptors in the transition of acute (AHF) to chronic HF (CHF). Risk-free 8-12 wk male C57BL/6 mice were subjected to MI surgery, and MI was confirmed by echocardiography and histology. Mass spectrometry was used to quantify sphingolipids in plasma, infarcted heart, spleen of mice, and ischemic and healthy human heart. The physiological cardiac repair was observed in mice with a notable increase of S1P quantity (pmol/g) in the heart and spleen significantly reduced in patients with ischemic HF. The circulating murine S1P levels were increased during AHF and CHF despite lowered substrate in CHF. The S1PR1 receptor expression was observed to coincide with the respective S1P quantity in mice and human hearts. Furthermore, selective S1P1 agonist limited inflammatory markers CCL2 and TNF-α and accelerated reparative markers ARG-1 and YM-1 in macrophages in the presence of Kdo2-Lipid A (KLA; potent inflammatory stimulant). This report demonstrated the importance of S1P/S1PR1 signaling in physiological inflammation during cardiac repair in mice. Alteration in these axes may serve as the signs of pathological remodeling in patients with ischemia.NEW & NOTEWORTHY Previous studies indicate that sphingosine-1-phosphate (S1P) has some role in cardiovascular disease. This study adds quantitative and integrative systems-based approaches that are necessary for discovery and bedside translation. Here, we quantitated sphinganine, sphingosine, sphingosine-1-phosphate (S1P) in mice and human cardiac pathobiology. Interorgan S1P quantity and respective systems-based receptor activation suggest cardiac repair after myocardial infarction. Thus, S1P serves as a therapeutic target for cardiac protection in clinical translation.

Entities:  

Keywords:  LC/MS; heart failure; ischemic heart disease; myocardial infarction; sphingosine-1-phosphate

Mesh:

Substances:

Year:  2021        PMID: 34415189      PMCID: PMC8461844          DOI: 10.1152/ajpheart.00314.2021

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  57 in total

1.  Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction.

Authors:  Małgorzata Knapp; Anna Lisowska; Piotr Zabielski; Włodzimierz Musiał; Marcin Baranowski
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-10-11       Impact factor: 3.072

Review 2.  Post-Myocardial Infarction Heart Failure.

Authors:  M Cecilia Bahit; Ajar Kochar; Christopher B Granger
Journal:  JACC Heart Fail       Date:  2018-03       Impact factor: 12.035

3.  Lipoxygenase inhibitor ML351 dysregulated an innate inflammatory response leading to impaired cardiac repair in acute heart failure.

Authors:  Bochra Tourki; Laurence M Black; Vasundhara Kain; Ganesh V Halade
Journal:  Biomed Pharmacother       Date:  2021-04-13       Impact factor: 6.529

Review 4.  Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism.

Authors:  Dagmar Meyer zu Heringdorf; Karl H Jakobs
Journal:  Biochim Biophys Acta       Date:  2006-10-04

Review 5.  Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association.

Authors:  Mercedes R Carnethon; Jia Pu; George Howard; Michelle A Albert; Cheryl A M Anderson; Alain G Bertoni; Mahasin S Mujahid; Latha Palaniappan; Herman A Taylor; Monte Willis; Clyde W Yancy
Journal:  Circulation       Date:  2017-10-23       Impact factor: 29.690

6.  Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation.

Authors:  Yonggang Ma; Ganesh V Halade; Jianhua Zhang; Trevi A Ramirez; Daniel Levin; Andrew Voorhees; Yu-Fang Jin; Hai-Chao Han; Anne M Manicone; Merry L Lindsey
Journal:  Circ Res       Date:  2012-12-20       Impact factor: 17.367

7.  Excess ω-6 fatty acids influx in aging drives metabolic dysregulation, electrocardiographic alterations, and low-grade chronic inflammation.

Authors:  Vasundhara Kain; Kevin A Ingle; Maureen Kachman; Heidi Baum; Gobinath Shanmugam; Namakkal S Rajasekaran; Martin E Young; Ganesh V Halade
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-10-06       Impact factor: 4.733

8.  Race-based and sex-based differences in bioactive lipid mediators after myocardial infarction.

Authors:  Ganesh V Halade; Vasundhara Kain; Chrisly Dillion; Mark Beasley; Tanja Dudenbostel; Suzanne Oparil; Nita A Limdi
Journal:  ESC Heart Fail       Date:  2020-05-04

9.  Myocardial infarction differentially alters sphingolipid levels in plasma, erythrocytes and platelets of the rat.

Authors:  Małgorzata Knapp; Małgorzata Zendzian-Piotrowska; Agnieszka Błachnio-Zabielska; Piotr Zabielski; Krzysztof Kurek; Jan Górski
Journal:  Basic Res Cardiol       Date:  2012-09-09       Impact factor: 17.165

10.  Reperfused vs. nonreperfused myocardial infarction: when to use which model.

Authors:  Merry L Lindsey; Lisandra E de Castro Brás; Kristine Y DeLeon-Pennell; Nikolaos G Frangogiannis; Ganesh V Halade; Caitlin C O'Meara; Francis G Spinale; Zamaneh Kassiri; Jonathan A Kirk; Petra Kleinbongard; Crystal M Ripplinger; Keith R Brunt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-06-11       Impact factor: 5.125

View more
  7 in total

Review 1.  Guidelines for in vivo mouse models of myocardial infarction.

Authors:  Merry L Lindsey; Keith R Brunt; Jonathan A Kirk; Petra Kleinbongard; John W Calvert; Lisandra E de Castro Brás; Kristine Y DeLeon-Pennell; Dominic P Del Re; Nikolaos G Frangogiannis; Stefan Frantz; Richard J Gumina; Ganesh V Halade; Steven P Jones; Rebecca H Ritchie; Francis G Spinale; Edward B Thorp; Crystal M Ripplinger; Zamaneh Kassiri
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-10-08       Impact factor: 5.125

2.  S100A9 is a functional effector of infarct wall thinning after myocardial infarction.

Authors:  Upendra Chalise; Mediha Becirovic-Agic; Michael J Daseke; Shelby R Konfrst; Jocelyn R Rodriguez-Paar; Dan Feng; Jeffrey D Salomon; Daniel R Anderson; Leah M Cook; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-12-10       Impact factor: 5.125

3.  Lymphatic endothelial sphingosine 1-phosphate receptor 1 enhances macrophage clearance via lymphatic system following myocardial infarction.

Authors:  Qinyu Li; Caixia Zhou; Kang Zhao; Yunhao Duan; Jinnan Yue; Xiuxiang Liu; Jinjin Wu; Shengqiong Deng
Journal:  Front Cardiovasc Med       Date:  2022-08-08

4.  Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation.

Authors:  Jenifer Masip; Rosa Jorba; Miguel López-Dupla; Pere Domingo; Yolanda María Pacheco; Graciano García-Pardo; Esteban Martínez; Consuelo Viladés; Sergi Veloso; Verónica Alba; Montserrat Olona; Francesc Vidal; Frederic Gómez-Bertomeu; Joaquim Peraire; Anna Rull
Journal:  Int J Mol Sci       Date:  2022-07-22       Impact factor: 6.208

Review 5.  Sphingolipid metabolism and signaling in cardiovascular diseases.

Authors:  Sonia Borodzicz-Jażdżyk; Piotr Jażdżyk; Wojciech Łysik; Agnieszka Cudnoch-Jȩdrzejewska; Katarzyna Czarzasta
Journal:  Front Cardiovasc Med       Date:  2022-08-31

Review 6.  The cardiosplenic axis: the prognostic role of the spleen in heart failure.

Authors:  Hiroaki Hiraiwa; Takahiro Okumura; Toyoaki Murohara
Journal:  Heart Fail Rev       Date:  2022-05-18       Impact factor: 4.654

7.  Therapeutic CFTR Correction Normalizes Systemic and Lung-Specific S1P Level Alterations Associated with Heart Failure.

Authors:  Franziska E Uhl; Lotte Vanherle; Frank Matthes; Anja Meissner
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.